# A Proof of Concept Study of the Safety, Tolerability, and Efficacy of Avastin (Bevacizumab) in Patients With Chemo-naive Chronic Lymphocytic Leukemia

> **NCT00754650** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 2 (actual)

## Conditions studied

- Lymphocytic Leukemia, Chronic

## Interventions

- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT00754650
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2014-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00754650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00754650, "A Proof of Concept Study of the Safety, Tolerability, and Efficacy of Avastin (Bevacizumab) in Patients With Chemo-naive Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00754650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*